Community Research and Development Information Service - CORDIS

H2020

SAPHIR Report Summary

Project ID: 633184
Funded under: H2020-EU.3.2.

Periodic Reporting for period 1 - SAPHIR (Strengthening Animal Production and Health through the Immune Response)

Reporting period: 2015-03-01 to 2016-08-31

Summary of the context and overall objectives of the project

The animal production sector suffers from important economic losses due to endemic infectious diseases, which hamper profitability, alter animal welfare, and lead to xenobiotic use with environmental consequences. Vaccination integrated in a global health management system is a sustainable, ethical and efficient preventive strategy against infectious diseases. However, many commercial vaccines are less than effective in the field or are simply not available. In the SAPHIR project, our goal is to develop animal vaccines against six major livestock pathogens: Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) and Mycoplasma (M.) hyopneumoniae in pigs, Eimeria species (E.) and Clostridium (C.) perfringens in chickens, Bovine Respiratory Syncytial Virus (BRSV) and Mycoplasma (M.) bovis in cattle. The challenge for these vaccines is to show high safety profiles, avoid pathogen evasion, trigger strong and life-long immunity, defend the mucosal portal of infection, be efficient at all age stages and in most individuals, be affordable and cost-effective, be used by farmers and demonstrate effectiveness in field conditions. Altogether the SAPHIR expected outcomes are new animals vaccines against a selection of representative livestock pathogens, integrated in a global health strategy, for optimal effectiveness and benefits to the livestock production sector and the society.

Work performed from the beginning of the project to the end of the period covered by the report and main results achieved so far

The results obtained during the first reporting period are :
1) Frameworks for assessing the economic impact of animal diseases and the vaccine perception by livestock producers
2) Pathogen specific vaccines :
- new attenuated vaccines, DNA vaccines and viral replicons against PRRSV
- bacterin from currently circulating strains and an ongoing strategy for a genetically attenuated vaccine against (M.) hyopneumoniae
- ongoing selection of genetically complemented Eimeria for multi-strain coverage
- protein candidates from a reverse vaccinology strategy against C. perfringens and M. bovis
- BRSV recombinant proteins given in one shot which protect calves with maternally derived antibodies
3) Generic vaccine strategies :
- a selection of immunostimulant adjuvants candidates tested in vitro for chicken and pigs
- skin patches loaded with PRRSV-DNA vaccines formulated on micro-particles and with inactivated PRRSV
- a selection of adjuvants efficient to stimulate cells from young aged animals (pig, chicken and cattle)
- sampling of large pig and chicken vaccinated cohorts to identify biomarkers which associate before vaccination with subsequent high and low vaccine responses
4) Translation to the market is worked out by the design of a close to the field experiment with a PRRSV vaccine candidate. The strategy to bring a second vaccine to demonstration has been drawn. Tools have been prepared to predict vaccine effectiveness in the field, i.e. 1) a wiki-site on the SAPHIR pathogen vaccine risks and 2) a first dynamic mechanistic model of the impact of several immune parameters on the control of PRRSV infection.
5) Dissemination and training are implemented through an active SAPHIR public website, newsletters, interaction with stakeholders, an integrated health strategies website and a training workshop on veterinary vaccinology shared with the H2020 PARAGONE project and the UK Veterinary Vaccinology Networks.

Progress beyond the state of the art and expected potential impact (including the socio-economic impact and the wider societal implications of the project so far)

Progress beyond the state-of-the-art for animal vaccines is to achieve effectiveness in the field, which requests to provide high safety profiles, avoid pathogen evasion, trigger strong and life-long immunity and be efficient at all age stages and in most individuals, defend the mucosal portal of infection, be cost-effective and used by farmers, and demonstrate effectiveness in field conditions. So far, the SAPHIR results respond to these challenges.

The SAPHIR expected impacts benefit to the :
- competitiveness of the animal production sector. The cost weight of diseases on production sectors and of antimicrobials and vaccines on disease management are being evaluated in SAPHIR.
- breeding companies. The markers of immunocompetence and the mathematical modeling tool that evaluates the impact of genetics in vaccine effectiveness will be useful for marker-assisted breeding.
- pharmaceutical industry. Vaccines and adjuvants responding to unmet needs are generated including vaccines efficient against genetically unstable pathogens, new combined vaccines, vaccines effective in one shot, and efficient DNA vaccines. The differential ELISA will be major pathogen control tools.
- public health. All SAPHIR pathogens are directly or indirectly responsible for high antimicrobial use, potentially generating antimicrobial-resistance and threats against the “One health” objective. The SAPHIR vaccine strategies will together lead to better control of bacterial diseases and thus decrease antibiotic use.
- protection of the environment and sustainability of the animal production sector. SAPHIR preventive strategies will enhance efficient use of scarce feed resources by improving feed conversion ratios and decreasing waste emission
- animal welfare. Vaccines and improved breeds will reduce death and suffering from endemic infectious diseases
- societal acceptance of vaccination. The effective and safe vaccines developed in SAPHIR, the one shot vaccine, as well as steps towards the development of better breeds, will contribute to improve the livestock producers’ acceptance and use of vaccines.

Related information

Follow us on: RSS Facebook Twitter YouTube Managed by the EU Publications Office Top